Skip to content
  • Home
  • World News
  • Business
  • Aviation
195 news

195News

All the news that's fit to print

  • Home
  • World News
  • Business
  • Aviation
  • Toggle search form
  • Staylist Bolsters Leadership with Addition of Clyde Earl Yelverton, III, Real Estate Expert, as Chief Operating Officer
    Staylist Bolsters Leadership with Addition of Clyde Earl Yelverton, III, Real Estate Expert, as Chief Operating Officer Business
  • Key Growth Drivers, Trends, From 2025 To 2034
    Key Growth Drivers, Trends, From 2025 To 2034 World News
  • Bombardier’s New Abu Dhabi Service Facility Highlights Ongoing Commitment to the Region as Customer Support Footprint Continues to Grow Around the World
    Bombardier’s New Abu Dhabi Service Facility Highlights Ongoing Commitment to the Region as Customer Support Footprint Continues to Grow Around the World Aviation
  • Global Artificial Intelligence AI Content Creation Tool Market Set For 16.7% Growth, Reaching .7 Billion By 2028
    Global Artificial Intelligence AI Content Creation Tool Market Set For 16.7% Growth, Reaching $1.7 Billion By 2028 World News
  • ONLY 10 DAYS UNTIL THE INTERNATIONAL SPACE DEVELOPMENT CONFERERENCE IN MAY 2023
    ONLY 10 DAYS UNTIL THE INTERNATIONAL SPACE DEVELOPMENT CONFERERENCE IN MAY 2023 Business
  • TES and Durapower to Collaborate on Lifecycle Management of Electric Vehicle Batteries
    TES and Durapower to Collaborate on Lifecycle Management of Electric Vehicle Batteries Business
  • Ritani Adds Colored Lab Diamonds to Inventory
    Ritani Adds Colored Lab Diamonds to Inventory Business
  • Agbotic Breaks Ground on Next SmartFarm in Ashford, CT
    Agbotic Breaks Ground on Next SmartFarm in Ashford, CT Business
Gb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study

Gb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study

Posted on October 24, 2022 By NewsEditor
Gb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal StudyGb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal StudyGb Sciences' anxiety formulations were previously identified using the company's AI-driven PhAROS™ platform, and they have now been evaluated using preclinical zebrafish models of stress at the National Research Council of Canada.

Gb Sciences’ Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study
GB Sciences


LAS VEGAS - October 24, 2022 - (Newswire.com)

Gb Sciences, Inc. ("GbS"; OTCQB:GBLX), a leading plant-inspired research and biopharmaceutical drug development company, has received positive preclinical results in an interim report from its study using preclinical zebrafish models of stress at the National Research Council of Canada (NRC). GbS' proprietary anxiety formulations have achieved a statistically significant reduction of stress in this preclinical study. The NRC is testing GbS' proprietary, psychotropic plant-based formulas for the treatment of depression and anxiety. GbS has leveraged its patent-pending PhAROS™ (Phytomedical Analytics for Research Optimization at Scale) platform to identify these combinations of plant compounds for novel drug candidates. These are the company's first non-cannabis formulations to advance in preclinical studies.

"We have achieved an important milestone in the development of our novel, kava-inspired anxiety formulations. Not only did some of our formulations achieve statistical significance in the animal model, but these minimum essential mixtures also demonstrated synergy by significantly outperforming the individual active ingredients within our minimum essential mixture formulations," said Dr. Andrea Small-Howard, Gb Sciences' President and Chief Science Officer. "This preclinical data also confirms that our PhAROS™ platform was capable of yielding concrete, potentially effective, plant-inspired combination drugs."

For these novel psychotropic drug candidates, the Gb Sciences research team used the PhAROS™ platform to identify new ingredients to improve upon an initial formulation for anxiety based on traditional medicine. The original plant mixture was derived from the kava plant, but some elements of kava are thought to cause liver toxicity. PhAROS™ identified ingredients from the Piper plant family as a substitute for the functionality of the ingredients in question without the potentially adverse safety profiles of those original ingredients. The Piper plant family includes pepper plants that are used worldwide in traditional medicines.

The PhAROSTM platform is a revolutionary, AI-driven science gateway and virtual research environment for drug discovery. With its data analytics and machine learning capabilities, PhAROS™ allows Gb Sciences to greatly reduce the time and money required to bring novel, plant-inspired formulations to market. PhAROS™ represents a breakthrough combination of data sciences and traditional plant-based medicines. 

To learn more about Gb Sciences, visit www.gbsciences.com.

About Gb Sciences and GbS Global Biopharma

Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The 'plant-inspired' active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences' intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences' lead program for Parkinson's disease is being prepared for a first-in-human clinical trial. Gb Sciences' formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada (NRC). The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com. 

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Media Contact

Alexis Quintal

[email protected]


Contact Information:
Madeleine Moench
[email protected]


Press Release Service by Newswire.com

Original Source: Gb Sciences' Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study
Business

Post navigation

Previous Post: Genomes Partners With CariGenetics to Launch a Decentralized Lab for Breast Cancer Research
Next Post: NREP Launched New Emergency Planning Professional Certification

Related Posts

  • Shylah Luna Honored with American Legal & Financial Network’s 2024 JPEG Picture the Future Award
    Shylah Luna Honored with American Legal & Financial Network’s 2024 JPEG Picture the Future Award Business
  • Deciding Between Two Job Offers?
    Deciding Between Two Job Offers? Business
  • Clear Ocean Group Sets New Sales Record in Caribe Plaza, San Juan
    Clear Ocean Group Sets New Sales Record in Caribe Plaza, San Juan Business
  • Anjali Byce Achieves Amazon Best-Seller Status with ‘Unlocking Success’ Book Co-Authored with Jack Canfield
    Anjali Byce Achieves Amazon Best-Seller Status with ‘Unlocking Success’ Book Co-Authored with Jack Canfield Business
  • United Partners and Vivactis Group Announce Strategic Collaboration
    United Partners and Vivactis Group Announce Strategic Collaboration Business
  • Investment Opportunities and Future Growth Prospects in Genetic Testing Market
    Investment Opportunities and Future Growth Prospects in Genetic Testing Market Business
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
« May    
last celebrity gossip
Gossip Stone - celebrity life and gossip

Recent Posts

  • Market Share, Segments, and Emerging TrendsJune 23, 2025
  • IMPORTANT NOTICE TO ARMADA WASTE MANAGEMENT/GPB WASTE MANAGEMENT INVESTORS WHO SUFFERED LOSSESJune 23, 2025
  • R2 Recycling Expands E-Waste Pickup Services for Businesses & SchoolsJune 23, 2025
  • IMPORTANT NOTICE TO GPB NYC DEVELOPMENT INVESTORS WHO SUFFERED LOSSESJune 22, 2025
  • Alexander Döll Appointed CEO of the Methanol InstituteJune 22, 2025
Brand Values Content
VUGA Enterprises - media network PR & Marketing
  • Leah Yosef Launches Centers of Influence Virtual Program
    Leah Yosef Launches Centers of Influence Virtual Program World News
  • War in Ukraine, Analytics. Day 1055: Whom Are Ukrainians Fleeing From? Putin or Their Own Governmnt?
    War in Ukraine, Analytics. Day 1055: Whom Are Ukrainians Fleeing From? Putin or Their Own Governmnt? World News
  • Designation of Paraguayan Officials Edgar Melgarejo, Jorge Bogarin, and Vicente Ferreira for Involvement in Significant Corruption
    Designation of Paraguayan Officials Edgar Melgarejo, Jorge Bogarin, and Vicente Ferreira for Involvement in Significant Corruption World News
  • War Day 575: War of Attrition Demands a Change of Style
    War Day 575: War of Attrition Demands a Change of Style World News
  • DeerTV Launches the Latest Outdoor Waterproof TV Cabinet
    DeerTV Launches the Latest Outdoor Waterproof TV Cabinet Business
  • Deputy Secretary Sherman’s Meeting with Belgian Foreign Minister Lahbib
    Deputy Secretary Sherman’s Meeting with Belgian Foreign Minister Lahbib World News
  • CC Wellness Wins 2023 Bronze Stevie Award for the ‘Most Innovative Company of the Year
    CC Wellness Wins 2023 Bronze Stevie Award for the ‘Most Innovative Company of the Year Business
  • Chainsaws Global Market 2024 To Reach .07 Billion By 2028 At Rate Of 10.5%
    Chainsaws Global Market 2024 To Reach $7.07 Billion By 2028 At Rate Of 10.5% World News
aerospace company
stem cell clinic in kiev
medical spa in miami
Fashion TV free

Copyright © 2023 195 News. All Rights Reserved by Coolaser | Partner of VUGA Enterprises |  Advertising: Get Published

Powered by .